New Study Confirms: COVID Vaccine During Pregnancy Does Not Increase Autism Risk in Children

A recent study confirmed that receiving the mRNA COVID-19 vaccine, either before or during pregnancy, is not associated with an increased risk of developmental disorders or autism in children.
The study included 434 children aged between 18 and 30 months, divided into two equal groups: the first group was born to mothers who received the mRNA vaccine during pregnancy or 30 days prior, while the second group was born to mothers who did not receive the vaccine.

Accurate Assessment of Neurological and Behavioral Development

The children underwent comprehensive assessment tests at ages 18 to 30 months, which included communication skills, gross and fine motor skills, problem-solving ability, social interaction, and behavioral patterns.
The results showed no differences between the two groups, indicating that the vaccine does not raise rates of autism or developmental delays.

Strict Scientific Standards and Ensuring Result Accuracy

The mothers were matched based on birthplace, medical history, type of health insurance, and ethnic background. Cases of very preterm birth, twins, or major congenital anomalies were excluded to ensure result accuracy.
The study was conducted within a network of clinical trials funded by the U.S. National Institutes of Health and followed strict standards for monitoring indicators of autism spectrum disorder and developmental delays.

Enhancing Confidence in mRNA Vaccines for Protection Against COVID Complications

These results are important to support doctors' recommendations for receiving mRNA vaccines during pregnancy, to protect both the mother and the infant from COVID-19 complications.
Although the follow-up extended only to two and a half years of age, the study provides strong reassurance to families and doctors regarding the absence of significant negative effects on children's neurological development in early years.